2型糖尿病并视网膜病变患者血浆趋化素水平与骨密度的关系

doi:10.3969/j.issn.1000-8535.2017.03.007

摘要/Abstract

摘要： 目的初步研究2型糖尿病并视网膜病变患者的血浆趋化素(chemerin)水平及其与骨密度的关系。方法选择150名糖尿病患者,按视网膜病变分为视网膜病变组(DR组)和眼底正常对照组(NDR组),采用全自动生化检测仪测定糖化血红蛋、甘油三脂、总胆固醇、低密度脂蛋白、高敏C反应蛋白;使用ELISA法检测血浆chemerin水平。骨密度采用双能X线骨密度仪分别测定腰椎正位(L2、L3、L4)、左侧股骨颈、大粗隆区、Ward's三角区的骨密度。结果 ①与NDR组相比,DR组的糖尿病病程较NDR组显著延长(P<0.05)。②DR组的TC、LDL-C、HbA1c、hs-CRP、chemerin水平较NDR组均显著升高(P<0.05)。③DR组的股骨颈、大粗隆区、Ward's三角区的骨密度较NDR组显著降低(P<0.05)。④血清chemerin水平与病程、BMI、HbA1C呈正相关,与股骨颈、大粗隆区、Ward's三角区的骨密度呈负相关。结论 DR患者的chemerin显著升高,chemerin可能参与DR的发生发展,并可能促使DR患者的骨密度降低。

关键词: 2型糖尿病, 视网膜病变, 趋化素, 骨密度

Abstract: Objective To explore the relationship between the circulation level of chemerin level and bone mineral density(BMD)in type 2 diabetes retinopathy patients. Methods A total of 150 patients with type 2 diabetes were selected. They were divided into two groups: retinopathy group(DR group), non- retinopathy group(NDR group). HbAlc, triglycerides(TC), total cholesterol(TG), low density lipoprotein cholesterol(LDL-C)and high-sensitivity C-reactive protein(hs-CRP)was measured by automatic biochemical detector. Bone mineral density was measured by the dual-energy X-ray absorptiometry. The BMD of lumbar vertebrae 2-4 and the left side of the femoral neck, the greater trochanter and Ward's triangle were assessed. Results ①Compared with the NDR group, the duration of diabetes in group DR was significantly longer(P<0.05); ②The levels of TC, LDL-C, HbA1c, hs-CRP and chemerin in DR group were significantly higher,③The BMD of the femoral neck, trochanter regionandward's triangle were significant reduction;④The level of chemerin was positively correlated with the duration of diabetes, BMI, HbA1C, and negatively correlated with the bone mineral density of the femoral neck, the greater trochanter, and the s' Ward triangle. Conclusion The level of chemerinin DR patients were significantly increased, and chemerin may play a role in the occurrence and development of DR, may promote the bone density decreased.

Key words: Type 2 diabetes mellitus, Retinopathy, Chemerin, Bone mineral density

银孟卓, 卢建文, 黄春苓. 2型糖尿病并视网膜病变患者血浆趋化素水平与骨密度的关系[J]. 广州医药, 2017, 48(3): 29-33.

YIN Mengzhuo, LU Jianwen, HUANG Chunling. Correlation study of chemerin level and bone mineral density in type 2 diabetes retinopathy patients[J]. Guangzhou Medical Journal, 2017, 48(3): 29-33.

参考文献

[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志, 2014 (07):447-498.
[2] WAKI H,TONTONTONOZ P.Endocrine functions of adipose tissue[J]. Annu Rev Pathol, 2007(2):31-56.
[3] BOZAOGLU K, BOLTON K, MCMILLAN J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J]. Endocrinology, 2007,148(10):4687-4694.
[4] 徐瑜, 毕宇芳, 王卫庆, 等.中国成人糖尿病流行与控制现状—2010年中国慢病监测暨糖尿病专题调查报告解读[J]. 中华内分泌代谢杂志,2014,30(03):184-186.
[5] TING D S, CHEUNG G C, WONG T Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review[J]. Clin Exp Ophthalmol, 2016,44(4):260-277.
[6] NEGLIAC,AGNELLON,ARGENTIEROA,et al. Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements[J]. J Biol Regul Homeost Agents,2014,28(4):733-741.
[7] LEIDIG-BRUCKNER G G,GROBHOLZ S,BRUCKNER T,et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus[J]. BMC Endocr Disord,2014,11:14-33.
[8] 陈曾,徐展望,向亮,等.脂肪因子chemerin 与骨质疏松症的关系展望[J]. 中国骨质疏松杂,2015(2):231-234;240.
[9] ROH S G,SONG S H,CHOI K C,et al. Chemerin——a new adipokine that modulates adipogenesis via its own receptor[J]. Biochem Biophys Res Commun, 2007,36(4):1013-1018.
[10] CHEW E Y, KLEIN M L, FERRIS F L, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22[J]. Arch Ophthalmol,1996,114(9):1079-1084.
[11] KAUR J, ADYA R, TAN B K, et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis[J]. Biochem Biophys Res Commun,2010,391(4):1762-1768.
[12] GILBERT M P,PRATLEY R E. Theimpact of diabetes and diabetes medications on bone health[J]. Endocrine Rev,2015,36(2):194-213.
[13] MELTON L J, LEIBSON C L, ACHENBACH S J, et al. Fracture risk in type 2 diabetes: update of a population-based study[J]. J Bone Miner Res,2008,23(8):1334-1342.
[14] CARNEVALE V, ROMAGNOLI E, D'ERASMO L, et al.Bone damage in type 2 diabetes mellitus[J]. Nutr Metab Cardiovasc Dis,2014,24(11):1151-1157.
[15] CAMPOS PASTOR M M, LOPEZ-IBARRA PJ, ESCOBAR-JIMENEZ F,et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study[J]. Osteoporos Int,2000,11(5):455-459.
[16] TERZOUDIS S, MALLIARAKI N, DAMILAKIS J, et al. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease[J]. Eur J GastroenterolHepatol, 2016,28(7):814-819.